Should Shares CRISPR Therapeutics Be a February Pick?
Biotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Be aware of common budgeting missteps that undermine goals. This overview highlights pitfalls and how to steer clear of them.
16,042 articlesBiotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Crypto markets closed an uneven week with Ethereum and XRP at critical junctures. This crypto price analysis february...
Meme coins linked to a president jumped on headlines about alien disclosure, led by the TRUMP token. The move faded a...
Bitcoin faced a rough weekend, dipping nearly 5% as macro signals collided with crypto headlines. This guide unpacks ...
Workday posted a solid Q4 beat on earnings and revenue, yet forward guidance disappointed investors. Shares tumbled a...
Mortgage rates fall below 6%, giving buyers a clearer affordability path as the spring home-buying season looms. Anal...
Futures point to a weaker start as AI fears push U.S. stocks being battered lower, even as international markets rall...
European inflows into crypto funds contrast with U.S. outflows, as data shows Europe buying dips while US funds bleed...
Geopolitical headlines drove a rush to buy the dip, yet the rebound failed to materialize for many investors. The epi...
GitLab beat Q4 on revenue and margins but issued FY27 guidance that disappointed investors, prompting nine analysts t...
Trade Desk stock jumped on reports of a potential partnership with OpenAI, signaling fresh AI-driven upside for ad-te...
The February 2026 jobs report shows a surprising payroll pullback, with 92,000 fewer positions. Unemployment rose to ...